Usefulness of bone markers for detection of bone metastases in lung cancer patients
- PMID: 12135691
- DOI: 10.1016/s0009-9120(02)00316-8
Usefulness of bone markers for detection of bone metastases in lung cancer patients
Abstract
Objectives: Lung cancer commonly causes destructive bone metastases. The aim of this study was to compare efficiency of biochemical bone markers in the detection of bone metastases in lung cancer patients.
Design and methods: We measured serum calcium (Ca), alkaline phosphatase (ALP), bone isoenzyme of alkaline phosphatase (BALP), osteocalcin (OC) and urine deoxypyridinoline crosslinks (DPD) levels in 52 lung cancer patients; 27 patients with the evidence of bone metastases, 25 without metastases in bone when they were first diagnosed. BALP, OC and DPD were measured by specific immunoassays. ALP, Ca and urine creatinine levels were determined by colorimetric methods.
Results: Ca, ALP, BALP, OC and DPD levels were significantly higher in the patients with bone metastases than those without bone metastases (p < 0.01 for BALP and OC, p < 0.001 for Ca, ALP and DPD). The sensitivity and specificities of all markers as follows: 89%-44% for BALP, 52%-88% for OC, 81%-76% for DPD, respectively. ROC curves were generated separately for BALP, OC and DPD to assess the diagnostic efficiency of markers in a different manner. DPD showed the best curve characteristics among the studied bone markers, followed by the BALP curve. OC curve showed poor characteristics.
Conclusions: Our results suggest that the measurement of DPD and BALP may be useful in detecting bone metastases in lung cancer patients. Also it could help in the follow-up of bone metastases from lung cancer since they can be repeated more often than roentgenography and bone scintigraphy, at less cost and with less discomfort to the patients.
Similar articles
-
Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.Clin Chem. 1999 Aug;45(8 Pt 1):1240-7. Clin Chem. 1999. PMID: 10430790 Clinical Trial.
-
Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.Anticancer Res. 2004 Sep-Oct;24(5B):3193-201. Anticancer Res. 2004. PMID: 15510610
-
Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer.Yonsei Med J. 2005 Jun 30;46(3):388-93. doi: 10.3349/ymj.2005.46.3.388. Yonsei Med J. 2005. PMID: 15988811 Free PMC article. Clinical Trial.
-
Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase.Clin Chim Acta. 1994 May;226(2):151-8. doi: 10.1016/0009-8981(94)90212-7. Clin Chim Acta. 1994. PMID: 7923810 Review.
-
The role of bone markers in metastatic bone disease.Cancer Treat Rev. 2006;32 Suppl 1:1-2. doi: 10.1016/s0305-7372(06)80001-0. Cancer Treat Rev. 2006. PMID: 16680830 Review.
Cited by
-
[Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases].Zhongguo Fei Ai Za Zhi. 2010 Oct;13(10):947-53. doi: 10.3779/j.issn.1009-3419.2010.10.04. Zhongguo Fei Ai Za Zhi. 2010. PMID: 20959067 Free PMC article. Clinical Trial. Chinese.
-
Diagnostic value of bone-specific alkaline phosphatase in lung carcinoma patients with bone metastases: a meta-analysis.Int J Clin Exp Med. 2015 Oct 15;8(10):17271-80. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26770319 Free PMC article.
-
[Semiquantitative parameters of 18F-FDG PET/CT, gene mutation states of epidermal growth factor receptor and anaplastic lymphoma kinase in prognosis evaluation of patients with lung adenocarcinoma].Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Oct 20;53(2):246-254. doi: 10.19723/j.issn.1671-167X.2021.02.003. Beijing Da Xue Xue Bao Yi Xue Ban. 2020. PMID: 33879893 Free PMC article. Chinese.
-
Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline.Med Oncol. 2005;22(2):195-201. doi: 10.1385/MO:22:2:195. Med Oncol. 2005. PMID: 15965284 Clinical Trial.
-
The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer.J Korean Med Sci. 2009 Apr;24(2):275-80. doi: 10.3346/jkms.2009.24.2.275. Epub 2009 Apr 21. J Korean Med Sci. 2009. PMID: 19399270 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical